Sulfaphenazole: A Benchmark Competitive CYP2C9 Inhibitor for Drug Metabolism and Vascular Research

Executive Summary: Sulfaphenazole is a potent, selective, and competitive inhibitor of cytochrome P450 2C9 (CYP2C9), with a Ki of 0.3 ± 0.1 μM under standard in vitro conditions (Chen et al., 2021). It exhibits minimal inhibition of related CYP isoforms (CYP2C8, CYP2C18) and none against CYP1A1, 1A2, 3A4, or 2C19 (APExBIO product sheet). Sulfaphenazole’s specificity allows for precise modulation of drug metabolism and investigation of pharmacogenetic outcomes. In diabetic db/db mouse models, daily intraperitoneal administration at 5.13 mg/kg for 8 weeks restored endothelial vasodilation by reducing oxidative stress and increasing nitric oxide bioavailability (related article). The compound is insoluble in water but dissolves in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL with ultrasonic assistance). Sulfaphenazole is provided by APExBIO (C4131) for research use only.

Biological Rationale

CYP2C9 is a major human drug-metabolizing enzyme, responsible for the clearance of numerous therapeutic agents, including oral anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), and oral hypoglycemics (Chen et al., 2021). Genetic polymorphisms in CYP2C9 lead to inter-individual variability in drug metabolism and risk of adverse drug reactions. Investigating CYP2C9-mediated metabolism is fundamental for optimizing drug dosing, predicting drug-drug interactions, and advancing pharmacogenetics. Sulfaphenazole serves as a reference inhibitor in these studies due to its high specificity and predictable activity profile (see related article—this article provides new experimental validation in diabetic vascular models).

Mechanism of Action of Sulfaphenazole

Sulfaphenazole is chemically defined as 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-benzenesulfonamide (CAS: 526-08-9; MW: 314.4). It acts as a competitive inhibitor by binding directly to the active site of CYP2C9, thereby blocking substrate access (Chen et al., 2021). This competitive binding is characterized by a Ki of 0.3 ± 0.1 μM, as measured in standard recombinant enzyme assays. Sulfaphenazole does not inhibit other major CYP isoforms (CYP1A1, 1A2, 3A4, 2C19) under comparable conditions, supporting its use in mechanistic studies of CYP2C9 without confounding off-target effects (APExBIO).

Evidence & Benchmarks

• Sulfaphenazole inhibits CYP2C9 competitively with a Ki of 0.3 ± 0.1 μM in vitro (Chen et al., 2021).
• It shows minimal inhibition for CYP2C8 and CYP2C18 (Ki >> 10 μM), and no inhibition for CYP1A1, 1A2, 3A4, or 2C19 in standard assays (APExBIO).
• In diabetic db/db mice, daily intraperitoneal dosing at 5.13 mg/kg for 8 weeks restored endothelium-dependent vasodilation, reduced oxidative stress, and increased nitric oxide bioavailability (see study).
• Structurally, the 4-aminobenzenesulfonamide moiety is essential for both anti-mycobacterial and CYP2C9 inhibitory activity (Chen et al., 2021).
• Analog optimization can reduce CYP2C9 inhibition while retaining antibacterial effects, as shown with compound 10d (MIC = 5.69 μg/mL, IC50 > 10 μM for CYP2C9) (see SAR study, Table 2).

Applications, Limits & Misconceptions

Sulfaphenazole is widely used for:

• Pharmacokinetic and pharmacogenetic studies to dissect CYP2C9-mediated drug metabolism (related—this article details new vascular endpoints).
• Adverse drug reaction risk assessments in preclinical models (see scenario-driven guidance—this article adds evidence-based storage and solubility guidance).
• Vascular endothelial function and oxidative stress research in diabetic disease models (see review—here, we provide new mechanistic and storage details).

Common Pitfalls or Misconceptions

• Not a broad-spectrum CYP inhibitor: Sulfaphenazole is ineffective on CYP1A1, 1A2, 3A4, and 2C19 isoforms under standard in vitro conditions (APExBIO).
• Not a diagnostic or therapeutic agent: Sulfaphenazole is strictly intended for scientific research and should not be used in humans or for clinical diagnostics.
• Solubility limitations: The compound is insoluble in water and requires DMSO or ethanol (with ultrasound) for stock solutions.
• Long-term solution instability: Sulfaphenazole solutions are not stable for prolonged storage; fresh preparation is recommended.
• Antibacterial activity is secondary: While structurally related to antibacterial sulfonamides, its primary use is as a CYP2C9 inhibitor, not an antibiotic (Chen et al., 2021).

Workflow Integration & Parameters

Preparation: Dissolve Sulfaphenazole in DMSO (≥13.15 mg/mL) or ethanol (≥9.92 mg/mL, ultrasound-assisted). Store solid at -20°C in a desiccated environment. Avoid repeated freeze-thaw cycles and do not store solutions long-term (APExBIO).

Experimental Use: For in vitro assays, titrate concentrations to ensure selective CYP2C9 inhibition (Ki ~0.3 μM). For in vivo vascular studies, use dosing regimens based on published models (e.g., 5.13 mg/kg i.p. daily for 8 weeks in mice). Always include appropriate controls and monitor for off-target effects.

Ordering & Documentation: Obtain the C4131 Sulfaphenazole reagent from APExBIO. Reference the product batch and lot in published work for reproducibility.

Conclusion & Outlook

Sulfaphenazole remains the gold-standard competitive CYP2C9 inhibitor for mechanistic studies of drug metabolism, adverse drug reactions, and vascular dysfunction. Its selectivity, potency, and reproducibility—especially as supplied by APExBIO—support its continued use in translational research. Ongoing analog optimization aims to retain beneficial properties while minimizing drug-drug interaction risk, expanding the toolkit for precision pharmacology (Chen et al., 2021).